<DrugInformationSummary id="CDR0000815621"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>Tarlatamab-dlle
         (Imdelltra) works by bringing healthy T cells (immune cells that help kill cancer cells) and lung cancer cells close together so the T cells can more effectively kill the lung cancer cells. It does this by binding to a protein called CD3 on healthy T cells and a protein called DLL3 on small cell lung cancer cells. Tarlatamab-dlle is a type of immunotherapy drug called a bispecific T-cell engager (BiTE).</DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/tarlatamab-dlle">Tarlatamab-dlle</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000792376">tarlatamab-dlle</TerminologyLink><GlossaryLink ref="CDR0000815619">tarlatamab</GlossaryLink><USBrandNames><USBrandName>Imdelltra</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>tar-LA-tah-mab</TermPronunciation><MediaLink ref="CDR0000816263" type="audio/mpeg" alt="" language="en" id="_3"/><MediaLink ref="CDR0000816264" type="audio/mpeg" alt="" language="es" id="_4"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e7b6163-5d83-42ea-82c9-cf7620cdc782&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Tarlatamab-dlle</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e7b6163-5d83-42ea-82c9-cf7620cdc782&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_1"><Title>Use in Cancer</Title>                                                              
  <Para id="_2">Tarlatamab-dlle
         is approved to treat:</Para>                          
  <ItemizedList Style="bullet" id="_3">
   <ListItem><Strong><GlossaryTermRef href="CDR0000045327" dictionary="Cancer.gov" audience="Patient">Small cell lung cancer</GlossaryTermRef></Strong>. It is used in adults with <GlossaryTermRef href="CDR0000045911" dictionary="Cancer.gov" audience="Patient">extensive-stage</GlossaryTermRef> cancer that got worse during or after treatment with <GlossaryTermRef href="CDR0000045841" dictionary="Cancer.gov" audience="Patient">platinum</GlossaryTermRef>-based chemotherapy.</ListItem>
   </ItemizedList>
  <Para id="_4">Tarlatamab-dlle
         is approved under FDAâ€™s Accelerated Approval Program. As a condition of approval, <GlossaryTermRef href="CDR0000799146" dictionary="Cancer.gov" audience="Patient">confirmatory trial(s)</GlossaryTermRef> must show that it provides a clinical benefit in these patients.</Para>
 </Section><Section id="_About"><Title>More About Tarlatamab-dlle</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/792376">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para>

<Para id="_About_8.26">MedlinePlus Information on <ExternalRef xref="https://medlineplus.gov/druginfo/meds/a624037.html">Tarlatamab-dlle</ExternalRef> - A lay language summary of important information about this drug that may include the following:</Para>
<ItemizedList Style="bullet" id="_About_9.27"><ListItem>warnings about this drug,</ListItem><ListItem>what this drug is used for and how it is used,</ListItem><ListItem>what you should tell your doctor before using this drug,</ListItem><ListItem>what you should know about this drug before using it, </ListItem><ListItem>other drugs that may interact with this drug, and</ListItem><ListItem>possible side effects.  </ListItem></ItemizedList><Para id="_About_10.28">Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for.  This patient information sheet applies only to approved uses of the drug.  However, much of the information may also apply to unapproved uses that are being studied.</Para></Section><Section id="_Research"><Title>Research Results and Related Resources</Title><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2023/tarlatamab-previously-treated-sclc">Tarlatamab Shows Promise for Some People with Small Cell Lung Cancer</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Therapy to Treat Cancer</ExternalRef></Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C175858">Find Clinical Trials for Tarlatamab-dlle</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2024-06-14</DateFirstPublished><DateLastModified>2025-01-07</DateLastModified></DrugInformationSummary>
